shutterstock_634058222_sergiy_palamarchuk

Sergiy Palamarchuk / Shutterstock.com

8 July 2021Big PharmaAlex Baldwin

Poland’s Polpharma asks US court to grant Swiss arbitration in TS case

Poland’s largest pharmaceutical company has asked the federal court to let it pursue arbitration in a Swiss court for a trade secrets dispute between India’s Rubicon Research and North Carolina biotech firm Kartha Pharmaceuticals.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

The European take on the Bolar provision: conclusions from Astellas v Polpharma

1 April 2013 While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.

US court resolves muscle relaxant dispute by enforcing arbitration award

20 July 2023 Polpharma’s injunction bid fails as motion is dismissed with prejudice | Court upholds Swiss Arbitration process.

More on this story

The European take on the Bolar provision: conclusions from Astellas v Polpharma

1 April 2013 While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.

US court resolves muscle relaxant dispute by enforcing arbitration award

20 July 2023 Polpharma’s injunction bid fails as motion is dismissed with prejudice | Court upholds Swiss Arbitration process.

More on this story

The European take on the Bolar provision: conclusions from Astellas v Polpharma

1 April 2013 While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.

US court resolves muscle relaxant dispute by enforcing arbitration award

20 July 2023 Polpharma’s injunction bid fails as motion is dismissed with prejudice | Court upholds Swiss Arbitration process.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages